MindMed CEO Sells 26,491 Shares for Tax Withholding 鈥� ~$180K Value

Q: How many MNMD shares did CEO Robert Barrow sell on June 25, 2025?

He sold 26,491 common shares according to the Form 4 filing.

Q: What was the weighted-average sale price of the shares?

The weighted-average price was $6.80 per share, with individual trades ranging from $6.67 to $7.03.

Q: How many MNMD shares does Robert Barrow still hold after the sale?

Barrow directly owns 830,065 shares following the reported transaction.

Q: Why were the shares sold under a Rule 10b5-1 plan?

The shares were sold to cover withholding taxes on vested RSUs, as permitted by a Rule 10b5-1 sell-to-cover election adopted on June 15, 2022.

[Form 4] Mind Medicine (MindMed) Inc. Insider Trading Activity

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MindMed (NASDAQ: MNMD) filed a Form 4 showing CEO & Director Robert Barrow sold 26,491 common shares on 25 Jun 2025 at a weighted-average price of $6.80. The sale, made under a pre-arranged Rule 10b5-1 plan, was solely to cover withholding taxes on recently vested RSUs. After the transaction, Barrow retains 830,065 shares of MindMed. No other insider trades or material changes were disclosed.

06/26/2025 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barrow Robert

(Last)

(First)

(Middle)

C/O MIND MEDICINE (MINDMED) INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK

10007

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Mind Medicine (MindMed) Inc. [ MNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	06/25/2025		S⁽¹⁾		26,491	D	$6.8⁽²⁾	830,065	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022.

2. The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many MNMD shares did CEO Robert Barrow sell on June 25, 2025?

He sold 26,491 common shares according to the Form 4 filing.

What was the weighted-average sale price of the shares?

The weighted-average price was $6.80 per share, with individual trades ranging from $6.67 to $7.03.

How many MNMD shares does Robert Barrow still hold after the sale?

Barrow directly owns 830,065 shares following the reported transaction.

Why were the shares sold under a Rule 10b5-1 plan?

The shares were sold to cover withholding taxes on vested RSUs, as permitted by a Rule 10b5-1 sell-to-cover election adopted on June 15, 2022.

AG真人官方

[Form 4] Mind Medicine (MindMed) Inc. Insider Trading Activity

FAQ

How many MNMD shares did CEO Robert Barrow sell on June 25, 2025?

What was the weighted-average sale price of the shares?

How many MNMD shares does Robert Barrow still hold after the sale?

Why were the shares sold under a Rule 10b5-1 plan?

NASDAQ:MNMD

MNMD Rankings

MNMD Latest News

MNMD Latest SEC Filings

MNMD Stock Data

AG真人官方

Trending News

[Form 4] Mind Medicine (MindMed) Inc. Insider Trading Activity

FAQ

How many MNMD shares did CEO Robert Barrow sell on June 25, 2025?

What was the weighted-average sale price of the shares?

How many MNMD shares does Robert Barrow still hold after the sale?

Why were the shares sold under a Rule 10b5-1 plan?

NASDAQ:MNMD

MNMD Rankings

MNMD Latest News

MNMD Latest SEC Filings

MNMD Stock Data